|
시장보고서
상품코드
2107759
무혈관성괴사 시장 : 약제 유형별, 투여 경로별, 유통 채널별, 지역별Avascular Necrosis Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
무혈관성괴사 시장은 2026년에 8억 950만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 12억 1,690만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 6.0%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 8억 950만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 6.00% | 2033년 시장 규모 예측 : | 12억 1,690만 달러 |
무혈관성괴사는 뼈로 가는 혈액 공급이 일시적 또는 영구적으로 차단됨으로써 발생하는 질환입니다. 뼈로 가는 혈액 공급이 차단되면 뼈에 미세한 균열이 생기고, 결국 뼈가 붕괴됩니다. 무혈관성괴사는 골괴사라고도 불립니다. 이 질환은 체내의 어느 뼈에서나 발생할 수 있지만, 주로 장골의 말단부에서 발생합니다. 골절이나 관절 탈구로 인해 뼈의 일부로 가는 혈류가 차단될 수 있습니다. 무혈관성괴사는 30세에서 50세 사이의 사람들에게서 가장 많이 나타납니다.
무혈관성괴사의 원인으로는 다음을 들 수 있습니다.
- 뼈에 가해진 외상.
- 골절.
- 혈관 손상.
- 코르티코스테로이드 등의 약물을 장기간 복용.
- 과도하고 장기간에 걸친 음주.
무혈관성괴사는 골스캔, 자기공명영상(MRI), 컴퓨터 단층촬영(CT) 및 X선 검사를 통해 진단됩니다. 무혈관성괴사 치료에 사용되는 약물로는 항응고제, 비스테로이드성 항염증약, 콜레스테롤 저하제 등이 있습니다.
시장 역학
예측 기간 중 신제품 출시 건수의 증가가 전 세계 무혈관성괴사 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2014년 9월, 제약 및 의약품 제조 기업인 바이엘 헬스케어 LLC는 미국에서 일반의약품 ‘알레베 PM’을 출시한다고 발표했습니다.
규제 당국의 의약품 승인 건수 증가가 전 세계 무혈관성괴사 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2019년 4월, 미국 식품의약국(FDA)은 골절 위험이 높은 폐경 후 여성의 골다공증 치료를 적응증으로 하는 스클레로스틴 억제제 ‘에베니티(Evenity, 로모소즈마브-aqqg)’를 승인했습니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 해설하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신약 출시 및 승인, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공합니다.
- 본 조사에서는 다음 매개변수를 바탕으로 전 세계 무혈관성괴사 시장의 주요 기업 개요을 소개하고 있습니다. : 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 및 전략, 그리고 향후 계획.
- 이 보고서에서 얻은 인사이트를 통해 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 ‘세계 무혈관성괴사 시장 보고서’는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 무혈관성괴사 시장 분석에 사용된 다양한 전략 매트릭스를 활용하여 원활하게 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 무혈관성괴사 시장 : 약제 유형별, 2021-2033년
제5장 세계의 무혈관성괴사 시장 : 투여 경로별, 2021-2033년
제6장 세계의 무혈관성괴사 시장 : 유통 채널별, 2021-2033년
제7장 세계의 무혈관성괴사 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSAAvascular Necrosis Market is estimated to be valued at USD 809.5 Mn in 2026 and is expected to reach USD 1,216.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 809.5 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.00% | 2033 Value Projection: | USD 1,216.9 Mn |
Avascular necrosis is a disease that results from the short-term or permanent loss of blood supply to the bone. This cut-off of blood supply to bone leads to tiny breaks in the bone and the bones eventually collapse. Avascular necrosis is also known as osteonecrosis. This condition may happen in any bone of the body, but mostly happens in the ends of a long bone. A broken bone or dislocated joint can interrupt the blood flow to a section of bone. Avascular necrosis condition is most common in people between the ages of 30 and 50.
Avascular necrosis can be caused due to-
- Injury to bone
- Fracture
- Damage of blood vessels
- Long-term use of medicines, such as corticosteroids
- Excessive, long-term use of alcohol
Avascular necrosis can be diagnosed by Bone scan, Magnetic Resonance Image and Computed Tomography, and X-rays. Medications used to treat avascular necrosis are blood thinners, nonsteroidal anti-inflammatory drugs, cholesterol lowering drugs and others.
Market Dynamics
Increasing number of product launches is expected to drive the growth of global avascular necrosis market during the forecast period. For instance, in September 2014, Bayer Healthcare LLC, a pharmaceutical and medicine manufacturing company, announced the launch of Aleve PM, an over-the-counter (OTC) pain reliever product in the U.S.
Increasing number of drug approvals from regulatory bodies is expected to drive the growth of the global avascular necrosis market. For instance, in April 2019, the U.S Food and Drugs Administration approved Evenity (romosozumab-aqqg), a sclerostin inhibitor indicated to treat osteoporosis in postmenopausal women at high risk of breaking a bone.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global avascular necrosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Solara Active Pharma Sciences Limited., Bayer AG, Rochem International, Inc., Alkem Labs., Dwarkesh Pharmaceuticals Private Limited., Novartis AG, GSK, and Pfizer Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global avascular necrosis market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global avascular necrosis market
Market Segmentation
- By Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
- Nonsteroidal anti-inflammatory drugs (Ibuprofen, Naproxen Sodium)
- Osteoporosis Drugs
- Cholesterol-lowering Drugs
- Blood Thinners
- Others
- By Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Injectable
- By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- South Africa
- Central Africa
- Key Players in the Avascular Necrosis Market
- Teva Pharmaceutical Industries Ltd.
- Reddy's Laboratories Ltd.
- Solara Active Pharma Sciences Limited
- Bayer AG
- Rochem International Inc.
- Alkem labs.
- Dwarkesh Pharmaceuticals Private Limited.
- Novartis AG
- GSK
- Pfizer, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Route of Administration
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Product Launches/Approvals
- Regulatory Scenario
- Epidemiology
- PEST Analysis
- Acquisition and Collaboration Scenario
4. Global Avascular Necrosis Market, By Drug Type, 2021 - 2033 (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Nonsteroidal anti-inflammatory drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
- Ibuprofen
- Naproxen Sodium
- Osteoporosis drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
- Cholesterol-lowering drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
- Blood Thinners
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
5. Global Avascular Necrosis Market, By Route of Administration, 2021 - 2033 (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
6. Global Avascular Necrosis Market, By Distribution Channel, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
7. Global Avascular Necrosis Market, By Region, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2022 - 2033
- Regional Trends
- North America
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of APAC
- Latin America
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Teva Pharmaceuticals Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Solara Active Pharma Sciences Limited.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Rochem International, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Alkem Labs.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Dwarkesh Pharmaceuticals Private Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GSK
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teva Pharmaceuticals Industries Ltd.
9. Section
- References
- Research Methodology
- About us and Sales Contact
